Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .

NCT Number	NCT05620784
Lead Sponsor	Northwestern University
Conditions	BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Enrollment	138 participants
Start Date	2023-03-01
Primary Completion	2023-06-06 (estimated)
Study Completion	2024-08-01 (estimated)
Updated on ClinicalTrials.gov	2023-09-13